LACTOLOGY FOUNDATION

Medicines in ATC class A03FA05 (alizapride) are dopamine D2‑receptor antagonist prokinetic antiemetics used primarily for the treatment and prevention of nausea and vomiting, including postoperative nausea and vomiting.medpedia.framar+4

Pharmacological class and ATC position

Alizapride belongs to the ATC subgroup A03FA “Propulsives”, which includes substituted benzamides and other agents that stimulate gastrointestinal motility.atcddd.fhi+2
It is a synthetic benzamide‑related dopamine D2 receptor antagonist with combined antiemetic and prokinetic properties, structurally related to metoclopramide and other benzamide prokinetics.wikipedia+3
Alizapride is available in oral and parenteral formulations (tablets, solutions for injection), reflecting its use in both ambulatory and peri‑operative settings.bbfarma+2

Mechanism of action and pharmacodynamics

Alizapride exerts its antiemetic effect through antagonism of D2 dopamine receptors in the chemoreceptor trigger zone (CTZ) located in the medulla, thereby interrupting emetic signaling from diverse stimuli.drugbank+3
By blocking peripheral D2 receptors in the gastrointestinal tract, alizapride enhances cholinergic activity and promotes upper gastrointestinal motility, improving gastric emptying and gastroduodenal transit (prokinetic effect).medchemexpress+2
It crosses the blood–brain barrier, which contributes to its clinical efficacy but also underlies central adverse effects such as acute dystonia and dyskinesia; its plasma half‑life is around 3 hours, necessitating repeated dosing for sustained effect.sciencedirect+2

Therapeutic indications

The core indications of alizapride are:

• Treatment of acute nausea and vomiting of various origins, including postoperative nausea and vomiting.drugs.ncats+4
• Prevention of nausea and vomiting associated with medical procedures, surgeries and certain cancer therapies where dopaminergic antiemetic action is useful.drugbank+2
• Symptomatic management of upper functional gastrointestinal complaints where prokinetic enhancement of gastric emptying contributes to relief, although this is usually a secondary indication to its antiemetic use.medchemexpress+1

As with all antiemetics, clinical use should be individualized, with reassessment if symptoms persist, to avoid masking serious underlying pathology.

Adverse effects and toxicological profile

The toxicological profile of alizapride is characterized by dopaminergic and extrapyramidal side effects, particularly at higher doses, rapid parenteral administration or in susceptible individuals.wikipedia+3
Commonly reported adverse reactions include somnolence, allergic reactions and skin rashes, as reflected in the Bulgarian product information and monograph.medpedia.framar
Because alizapride crosses the blood–brain barrier, it can precipitate transient extrapyramidal motor disorders such as acute dystonia, dyskinesia and akathisia, mirroring the class effects seen with other centrally acting D2 antagonists.sciencedirect+3

Longer‑term or high‑dose therapy may theoretically carry risks of tardive dyskinesia and hyperprolactinemia, although detailed chronic‑use data for alizapride itself are more limited than for better‑studied benzamides like metoclopramide.clevelandclinic+2
From a toxicological practice perspective, A03FA05 medicines should be avoided or used with particular caution in patients with a history of neuroleptic‑induced extrapyramidal reactions, movement disorders or marked dopaminergic sensitivity.wikipedia+2

Contraindications and special precautions

Typical contraindications and precautions for alizapride include:

• Hypersensitivity to alizapride or any excipient in the medicinal product, explicitly listed as a contraindication in the Framar/medpedia monograph.medpedia.framar
• Clinical scenarios of gastrointestinal perforation, mechanical obstruction or hemorrhage, in which increased motility can aggravate the condition; in such cases propulsives are generally contraindicated.wikipedia+1
• Caution in children, adolescents and older adults because of higher susceptibility to extrapyramidal reactions and neurotoxicity from central D2 antagonists.clevelandclinic+2

Concomitant use with other dopamine antagonists (antipsychotics, metoclopramide, certain antiemetics) may increase the risk of extrapyramidal toxicity and should prompt dose adjustment or drug selection review.wikipedia+2
Clinicians should also evaluate potential interactions with medicines that affect cardiac conduction or serotonergic modulation, based on national product information, as antiemetic polypharmacy can amplify systemic toxicity.drugbank+2

Use in pregnancy and lactation

Evidence‑based general guidance on breastfeeding and medications indicates that most drugs appear in breast milk in small amounts, and many can be used compatibly when maternal benefit is clear and infant risk is low.mayoclinic+2
Specific lactation data for alizapride are limited and not well characterized in standard references, so risk assessment must rely on class properties of centrally penetrating D2‑antagonist benzamides and on external databases such as LactMed.appleyoutubeuhsp.libguides
Given its ability to cross the blood–brain barrier and provoke extrapyramidal effects, there is a theoretical concern that significant exposure in the breastfeeding infant could cause sedation, feeding difficulties or abnormal movements, especially in premature or medically fragile infants.sciencedirect+2

A toxico‑lactological, practice‑oriented approach to alizapride in lactation would be:

• Prefer alternative antiemetics with more favorable and better documented breastfeeding safety (for example, selected 5‑HT3 antagonists or antihistamines), particularly for repeated or prolonged use.cdc+2
• If alizapride is deemed necessary (e.g. limited access to alternatives or specific clinical scenarios), use the lowest effective dose for the shortest possible duration, with close observation of the infant for sedation, poor feeding, irritability or extrapyramidal signs.breastfeeding+2
• In high‑risk infants (premature, low birth weight, significant comorbidities), avoid alizapride where feasible and prioritize agents with robust lactation data, reserving alizapride for exceptional cases under specialist supervision.uhsp.libguides+3

Practical dosing remarks

Defined daily dose (DDD) values for alizapride in the ATC/DDD system are 0.15 g orally and 0.15 g parenterally, reflecting its typical daily quantitative exposure in adults.atcddd.fhi+1
Actual clinical dosing regimens, frequency and treatment duration are specified in national summaries of product characteristics and must be strictly followed; prescribers should avoid empirical dose escalation or prolonged continuous therapy without reassessing indication and toxicity risk.pharmastatus+3

Toxico‑lactological categorization (innovative practice‑oriented model)

Integrating the above pharmacological and lactation‑related considerations, alizapride (ATC A03FA05) occupies a distinct position in our toxico‑lactological framework:

• Centrally penetrating dopamine D2 antagonist with proven antiemetic and prokinetic efficacy.
• Limited direct human lactation data, but meaningful potential for central nervous system and extrapyramidal toxicity in both mother and infant.
• Clinical role often focused on short‑term control of severe nausea and vomiting, particularly around surgery or procedures, rather than chronic functional gastrointestinal therapy.drugs.ncats+4

Accordingly, we assign alizapride to the following category in our innovative toxico‑lactological classification:

Category: “Restrictive use in lactation: centrally acting dopaminergic prokinetics with extrapyramidal risk” – generally not preferred in breastfeeding women; may be considered only for brief, strictly indicated courses when safer antiemetics are unavailable or unsuitable, under specialist decision‑making, with enhanced infant monitoring and avoidance of repeated or long‑term administration.mayoclinic+5

These are our innovative toxico‑lactological categories, developed and proposed by our team to colleagues worldwide as more adaptogenic to routine clinical practice and more ultimate as guidance for practical therapeutic choice than traditional, purely theoretical risk labels.uhsp.libguides+3
The model aims to synthesize pharmacodynamics, toxicological patterns, route and duration of exposure, and real‑world breastfeeding constraints into a single, clinically usable decision axis for busy healthcare professionals.